Now rising at Penn Medicine.
The Abramson Cancer Center is honored to be accepted as a member of the National Cancer Center Network (NCCN), an alliance of the top academic cancer centers in the US.
A new immunotherapy developed at Penn may be the world’s best hope against the world’s most aggressive cancer: glioblastoma.
We are ranked #1 in the Philadelphia region and 10th in the nation for cancer care by U.S. News & World Report.
CAR-T cell therapy was recently approved by the FDA to treat young adults with acute lymphocytic leukemia and adults with non-Hodgkin lymphoma. There are also clinical trials available for all different types of cancer.
Whether you are newly diagnosed with cancer or looking for a second opinion, request a call back and find out if CAR-T is right for you.
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.